BALTIMORE, Md., July 8, 2026
Longeviti Neuro Solutions has unveiled ClearFit AI™, an innovative Brain Ultrasound Interface (BUI) platform designed to transform post-operative brain imaging through the integration of FDA-cleared sonolucent cranial implant technology, bedside ultrasound, and artificial intelligence. The newly launched platform establishes a persistent acoustic window to the brain, allowing clinicians to perform real-time bedside ultrasound imaging following neurosurgical procedures while reducing dependence on conventional imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI). By combining advanced implant technology with AI-enhanced ultrasound visualization, ClearFit AI™ introduces a new category of neurosurgical imaging that has the potential to improve clinical workflow, accelerate patient assessment, and support future innovations in precision neurological care. The platform reflects Longeviti’s long-term vision of advancing scalable neurotechnology solutions that improve post-operative monitoring while enhancing both patient outcomes and healthcare efficiency.
AI-Enabled Brain Ultrasound Platform Expands Bedside Neuroimaging
The ClearFit AI™ platform integrates several complementary technologies into a unified clinical solution, including ClearFit® sonolucent cranial implants, ultrasound compatibility, AI-assisted image optimization, and clinical workflow support. Together, these components establish the Brain Ultrasound Interface (BUI), enabling physicians to obtain direct bedside visualization of intracranial structures through the implanted acoustic window.
Unlike conventional postoperative imaging that frequently requires transporting critically ill patients for CT or MRI examinations, the BUI platform enables ultrasound-based brain assessment directly at the patient’s bedside, supporting faster clinical decision-making and reducing operational complexity. AI-enhanced imaging capabilities available on compatible ultrasound systems further optimize visualization, allowing clinicians to obtain clearer and more consistent images during postoperative monitoring. The persistent ultrasound interface also creates opportunities for future neurological applications currently under investigation, positioning the technology as a scalable platform capable of supporting advances in neurosurgery, neurocritical care, and precision brain imaging.
Technology Aims to Improve Clinical Workflow and Patient Care
Advertisement
As healthcare providers increasingly seek cost-effective technologies capable of improving workflow efficiency and expanding access to diagnostic imaging, ultrasound-based postoperative neuroimaging offers significant operational potential. The Brain Ultrasound Interface may help reduce reliance on repeated CT and MRI examinations, minimize patient transport within hospitals, improve imaging accessibility in intensive care units, and streamline postoperative neurological assessments. For patients recovering from brain surgery, bedside ultrasound imaging may reduce exposure to ionizing radiation, eliminate unnecessary movement during critical recovery periods, and support continuous monitoring from the intensive care unit through outpatient follow-up.
Company leadership emphasized that the platform represents more than a single medical device, describing it as a foundation for future AI-assisted neurosurgical care and advanced neurological monitoring. Built upon FDA-cleared implant technology, the ClearFit AI™ platform is designed to integrate seamlessly into existing neurosurgical workflows while supporting future research into artificial intelligence-driven brain imaging applications. As AI continues reshaping medical imaging and precision medicine, Longeviti Neuro Solutions is positioning ClearFit AI™ at the forefront of next-generation neurotechnology by combining implant innovation, bedside ultrasound, and intelligent image analysis into a scalable platform that could redefine postoperative brain visualization and neurological patient management.
Source: Longeviti press release
